Friday, August 29, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Immunotherapy post-surgery improves overall survival for kidney cancer

April 17, 2024
in Cancer
Reading Time: 4 mins read
0
Dana-Farber led research shows immunotherapy post-surgery improves overall survival for kidney cancer
65
SHARES
593
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

Boston – For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

Dana-Farber led research shows immunotherapy post-surgery improves overall survival for kidney cancer

Credit: Dana-Farber Cancer Institute

Boston – For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence, according to an analysis of results from the KEYNOTE-564 study. Pembrolizumab was associated with a 38% reduction in risk of death compared with placebo.

“We can now tell our patients that pembrolizumab after surgery not only delays recurrences but also helps them live longer,” said the study’s lead investigator Toni Choueiri, MD, of Dana-Farber Cancer Institute.

Choueiri, director of the Lank Center for Genitourinary Oncology at Dana-Farber, is the first author of the study published today in the New England Journal of Medicine. Choueiri previously presented the findings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium on January 27, 2024.

The KEYNOTE-564 trial was designed to evaluate adjuvant pembrolizumab following nephrectomy (removal of the cancerous kidney) within 12 weeks prior to randomization. The double-blind, phase 3 study, carried out at hundreds of sites internationally, enrolled 994 patients who were randomized to pembrolizumab once every three weeks for about a year, or a placebo. Pembrolizumab targets a molecular pathway that cancer cells commandeer to evade attack by the body’s immune system. By blocking this “checkpoint” pathway, the drug helps free the immune system’s army of T cells to combat tumors.

For inclusion in the trial, patients had to have a clear-cell component to their tumor and be at intermediate or high risk of recurrence. Some patients with resected metastases after nephrectomy were also eligible. For patients with ccRCC, surgery is intended to be curative. However, between 30 and 50% of patients can experience recurrence after surgery. Recurrences often result in metastatic disease, which is usually incurable.

Investigators have been trying to find ways to reduce recurrences and prolong survival for this patient group since 1973, the date of the first randomized controlled trial of an adjuvant therapy. An adjuvant therapy is a medicine intended to enhance efficacy after primary treatment of the cancer, which in this case is surgery.

“Since 1973, more than 12,000 patients with kidney cancer participated in adjuvant studies versus a control arm and none of the studies showed the experimental arm extends lives until now with the KEYNOTE-564 study,” says Choueiri. “We showed pembrolizumab extends survival. It doesn’t only delay recurrence.”

In the first interim analysis of the KEYNOTE-564 study, Choueiri and colleagues reported that adjuvant pembrolizumab improved disease-free survival in patients with kidney cancer at high risk of relapse. Pembrolizumab was approved in 2021 as adjuvant treatment for patients with kidney cancer based on these KEYNOTE-564 results.

This third interim analysis was completed after a median of 57.2 months of follow up. Adjuvant pembrolizumab significantly prolonged overall survival versus placebo in trial participants. Overall survival benefits with pembrolizumab were consistent across subgroups, irrespective of stage, risk stratification, immunological biomarkers, and other characteristics.

Approximately 18% of patients stopped therapy due to side-effects associated with pembrolizumab. No treatment related deaths were reported with pembrolizumab. The investigators reported previously that adjuvant pembrolizumab did not result in clinically meaningful deterioration of health-related quality of life.

Prior to the approval of pembrolizumab, there was no widespread accepted standard of care for patients with ccRCC after treatment with surgery. Now, with adjuvant pembrolizumab as standard of care for this patient group, Choueiri and colleagues are investigating whether it can be improved by combining pembrolizumab with the HIF-2 inhibitor belzutifan.

Funding: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co.

*This press release was initially issued on January 27, 2024. It has been updated and re-issued to reflect publication in the New England Journal of Medicine.

About Dana-Farber Cancer Institute 

Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.



Journal

New England Journal of Medicine

DOI

10.1056/NEJMoa2312695

Method of Research

Randomized controlled/clinical trial

Article Title

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Article Publication Date

18-Apr-2024

Share26Tweet16
Previous Post

Weather and climate extremes in 2023 impacting the globe with emerging features

Next Post

Protecting brain cells with cannabinol

Related Posts

blank
Cancer

Mesenchymal Stem Cells: Beneficial or Harmful in AML?

August 28, 2025
blank
Cancer

New Insights into Breast Reconstruction Preferences Among African American Women Published in Plastic and Reconstructive Surgery

August 28, 2025
blank
Cancer

New CEA-Based Surveillance Boosts Gastric Cancer

August 28, 2025
blank
Cancer

MERIT Grant Secured to Advance HIV Cure Research

August 28, 2025
blank
Cancer

New Study Reveals Key Mechanisms Behind Cancer Cell Response and Resistance to Treatment

August 28, 2025
blank
Cancer

Immune Cell Therapy Shows Promise in Stabilizing Advanced Head and Neck Cancer

August 28, 2025
Next Post
Authors

Protecting brain cells with cannabinol

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27541 shares
    Share 11013 Tweet 6883
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    954 shares
    Share 382 Tweet 239
  • Bee body mass, pathogens and local climate influence heat tolerance

    642 shares
    Share 257 Tweet 161
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    509 shares
    Share 204 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    312 shares
    Share 125 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Revolutionizing Primary Care with Generative AI Solutions
  • Transplant Policies: Undocumented Immigrants vs. Tourists
  • Enhanced Outcomes with Revised Oocyte Warming Protocol
  • Completing the Loop: A 360° Journey in Biomedical Engineering

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,859 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading